Trial Profile

Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab (Tecentriq) in Local Head and Neck Squamous Cell Carcinoma (the PIONEER Trial)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Simlukafusp alfa (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms PIONEER; the PIONEER Trial

Most Recent Events

24 Apr 2024 Status changed from recruiting to completed.
13 Apr 2024 This trial has been Discontinued in Germany, according to European Clinical Trials Database record.
10 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com